Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Yanxiang Zou"'
Autor:
Xiaoqiang Liu, Zhonghan Sun, Zhongfang Wang, Jingjing Chen, Qianhui Wu, Yan Zheng, Xiaoyun Yang, Luhui Mo, Xuemei Yan, Wei Li, Yanxiang Zou, Huiling Song, Feng Qian, Jing Lu, Hui Zhou, Yaping Wang, Zuoyun Xiang, Hongjie Yu, Jinzhong Lin, Lin Yuan
Publikováno v:
EClinicalMedicine, Vol 64, Iss , Pp 102231- (2023)
Summary: Background: Heterologous vaccine schedules have been recommended to provide superior immunity and protection against emergent SARS-CoV-2 variants of concern. We aimed to evaluate the safety, immunogenicity, and efficacy of an mRNA COVID-19 v
Externí odkaz:
https://doaj.org/article/b56c6bc02eb0406498fbdbad12b39669
Autor:
Yan Zheng, Zhifang Ying, Yanxiang Zou, Taotao Zhu, Dinggu Qian, Weixiao Han, Ya Jiang, Zhiwei Jiang, Xingyan Li, Jianfeng Wang, Jin Lei, Li Xu, Deyu Jiang, Changgui Li, Xiaoqiang Liu
Publikováno v:
Vaccines, Vol 10, Iss 2, p 254 (2022)
Background: The Sabin-strain-based inactivated poliovirus vaccine (sIPV) plays an important role in poliomyelitis eradication in developing countries. As part of the phase III clinical development program, this study aimed to evaluate the safety, imm
Externí odkaz:
https://doaj.org/article/8f03e541be8c4179b419867d0315f6a2
Autor:
Yan Zheng, Pingfang Cui, Runxiang Long, Ruiju Jiang, Hongbo Chen, Dandan Li, Ying Zhang, Chen Cheng, Yuehui Zhang, Yi Pu, Weiwu Chen, Jianfeng Wang, Zhanlong He, Jing Pu, Meijian Zhou, Qihan Li, Guorun Jiang, Donglan Liu, Zhifang Yin, Yan Li, Jin Lei, Zhimei Zhao, Shengtao Fan, Yanchun Che, Li Yu, Ya Jiang, Heng Zhao, Yaling Zhou, Yanxiang Zou, Kai-Li Ma, Ting Yang, Zhongping Xie, Huijuan Yang, Yun Liao, Xingli Xu, Changgui Li, Jianbo Yang, Chao Hong, Qiongzhou Yin, Yingqiu Guo, Mingjue Xu, Jingyu Li, Youshuai Zhu, Hongling Zhao, Xiaoqiang Liu, Lichun Wang
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases
Clinical Infectious Diseases
Background We evaluated an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine for immunogenicity and safety in adults aged 18–59 years. Methods In this randomized, double-blinded, controlled trial, healthy adults recei